Atara Biotherapeutics, Inc. (ATRA): Capital Expenditures
$0
Year ended 2025-12-31
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $0 | -100.0% | 2026-03-16, From 2025-01-01 |
| 2024-12-31 | $246.0K | -79.9% | 2026-03-16, From 2024-01-01 |
| 2023-12-31 | $1.22M | -70.8% | 2025-03-07, From 2023-01-01 |
| 2022-12-31 | $4.19M | -60.4% | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | $10.58M | +134.4% | 2023-02-08, From 2021-01-01 |
| 2020-12-31 | $4.51M | -21.3% | 2023-02-08, From 2020-01-01 |
| 2019-12-31 | $5.73M | -84.0% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $35.92M | +77.6% | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $20.23M | +569.9% | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | $3.02M | +941.4% | 2019-02-26, From 2016-01-01 |
| 2015-12-31 | $290.0K | +530.4% | 2018-02-27, From 2015-01-01 |
| 2014-12-31 | $46.0K | n/m | 2017-03-09, From 2014-01-01 |
| 2013-12-31 | $3.0K | n/a | 2016-03-04, From 2013-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $0 | -100.0% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $4.70M | +17.9% |
| Agenus Inc (AGEN) | 2025-12-31 | $6.0K | -99.0% |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | $3.85M | -44.2% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $848.0K | +450.6% |
| Beam Therapeutics Inc. (BEAM) | 2025-12-31 | $14.95M | +67.1% |
| Ginkgo Bioworks Holdings, Inc. (DNA) | 2025-12-31 | $7.67M | -87.7% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $2.41M | -0.9% |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | $536.0K | -85.8% |
Compare ATRA, GLUE, AGEN, IBRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗